BVS Stock Analysis: Bioventus | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 710m USD | 12M Return: 60.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.45M
Qual. Beats: 1
Rev. Trend: 91.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bioventus Inc. (BVS) is a U.S.-based medical device company that develops pain relief and musculoskeletal therapies, selling to healthcare institutions, physicians, patients, and distributors across the United States and internationally. Its portfolio spans hyaluronic acid injections for knee osteoarthritis, peripheral nerve stimulation products, ultrasonic surgical systems for spine and neurological procedures, bone graft substitutes, and ultrasound-based bone healing devices such as Exogen. Founded in 2011 and headquartered in Durham, North Carolina, the company completed its initial public offering in February 2021 and operates within the Health Care Equipment sub-industry. As a small-cap medical device firm, Bioventus derives revenue primarily from recurring sales of procedure-dependent consumables (such as injectable treatments and graft substitutes) as well as durable surgical capital equipment.
- HA injection reimbursement pressure threatens Durolane osteoarthritis sales
- Surgical Solutions and BoneScalpel adoption drive high-margin revenue mix
- CartiHeal integration and leverage limit near-term margin recovery
| Net Income: 28.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 12.01 > 1.0 |
| NWC/Revenue: 17.65% < 20% (prev 13.14%; Δ 4.51% < -1%) |
| CFO/TA 0.16 > 3% & CFO 102.9m > Net Income 28.5m |
| Net Debt (256.4m) to EBITDA (103.3m): 2.48 < 3 |
| Current Ratio: 1.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.0m) vs 12m ago 6.06% < -2% |
| Gross Margin: 67.78% > 18% (prev 67.17%; Δ 0.61% > 0.5%) |
| Asset Turnover: 85.89% > 50% (prev 82.11%; Δ 3.78% > 0%) |
| Interest Coverage Ratio: 2.44 > 6 (EBIT TTM 56.9m / Interest Expense TTM 23.3m) |
| A: 0.16 (Total Current Assets 249.8m - Total Current Liabilities 148.1m) / Total Assets 650.5m |
| B: -0.51 (Retained Earnings -331.8m / Total Assets 650.5m) |
| C: 0.08 (EBIT TTM 56.9m / Avg Total Assets 671.0m) |
| D: 0.45 (Book Value of Equity 188.9m / Total Liabilities 416.3m) |
| Altman-Z'' = 0.41 = B |
| DSRI: 1.01 (Receivables 120.5m/118.1m, Revenue 576.3m/567.7m) |
| GMI: 0.99 (GM 67.17% / 67.78%) |
| AQI: 0.97 (AQ_t 0.58 / AQ_t-1 0.59) |
| SGI: 1.02 (Revenue 576.3m / 567.7m) |
| TATA: -0.11 (NI 28.5m - CFO 102.9m) / TA 650.5m) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 11.88 with a total of 626,143 shares traded. Over the past week, the price has changed by +13.36%, over one month by +31.27%, over three months by +31.13% and over the past year by +60.76%.
Current recommended Stop Loss: 10.50 (which is 11.6% or 2.4 ATR below the current price).
Bioventus has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy BVS.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.8 | 24.6% |
P/E Trailing = 25.561
P/E Forward = 13.5135
P/S = 1.3848
P/B = 3.7586
P/EG = 1.3523
Revenue TTM = 576.3m USD
EBIT TTM = 56.9m USD
EBITDA TTM = 103.3m USD
Long Term Debt = 253.3m USD (from longTermDebt, last quarter)
Short Term Debt = 18.8m USD (from shortTermDebt, last quarter)
Debt = 292.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 20.2m
Net Debt = 256.4m USD (calculated: Debt 292.3m - CCE 35.8m)
Enterprise Value = 966.4m USD (710.0m + Debt 292.3m - CCE 35.8m)
Interest Coverage Ratio = 2.44 (Ebit TTM 56.9m / Interest Expense TTM 23.3m)
EV/FCF = 9.60x (Enterprise Value 966.4m / FCF TTM 100.6m)
FCF Yield = 10.41% (FCF TTM 100.6m / Enterprise Value 966.4m)
FCF Margin = 17.46% (FCF TTM 100.6m / Revenue TTM 576.3m)
Net Margin = 4.94% (Net Income TTM 28.5m / Revenue TTM 576.3m)
Gross Margin = 67.78% ((Revenue TTM 576.3m - Cost of Revenue TTM 185.7m) / Revenue TTM)
Gross Margin QoQ = 67.88% (prev 68.07%)
Tobins Q-Ratio = 1.49 (Enterprise Value 966.4m / Total Assets 650.5m)
Interest Expense / Debt = 7.97% (Interest Expense 23.3m / Debt 292.3m)
Taxrate = 12.64% (571k / 4.52m)
NOPAT = 49.7m (EBIT 56.9m * (1 - 12.64%))
Current Ratio = 1.69 (Total Current Assets 249.8m / Total Current Liabilities 148.1m)
Debt / Equity = 1.55 (Debt 292.3m / totalStockholderEquity, last quarter 188.9m)
Debt / EBITDA = 2.48 (Net Debt 256.4m / EBITDA 103.3m)
Debt / FCF = 2.55 (Net Debt 256.4m / FCF TTM 100.6m)
Total Stockholder Equity = 175.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.24% (Net Income 28.5m / Total Assets 650.5m)
RoE = 16.27% (Net Income TTM 28.5m / Total Stockholder Equity 175.1m)
RoCE = 13.29% (EBIT 56.9m / Capital Employed (Equity 175.1m + L.T.Debt 253.3m))
RoIC = 10.10% (NOPAT 49.7m / Invested Capital 492.4m)
WACC = 6.73% (E(710.0m)/V(1.00b) * Re(6.64%) + D(292.3m)/V(1.00b) * Rd(7.97%) * (1-Tc(0.13)))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 4.79%
[DCF] Terminal Value 77.97% ; FCFF base≈69.9m ; Y1≈80.2m ; Y5≈118.0m
[DCF] Fair Price = 22.43 (EV 1.78b - Net Debt 256.4m = Equity 1.52b / Shares 67.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.27 | # QB: 1
Revenue Correlation: 91.55 | Revenue CAGR: 5.28% | SUE: 0.44 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.22 | Chg30d=+0.00% | Revisions=-50% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.18 | Chg30d=+0.00% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=0.78 | Chg30d=+0.00% | Revisions=+50% | GrowthEPS=+14.1% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=0.91 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+16.8% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: +27% (up=8, down=4)